Phase II study to evaluate the activity and safety of TH-302 in combination with subitinib for patients with previously untreated metastatic well or moderately differentiated pancreatic neuroendocrine tumors (pNET)
INDEPENDENT CLINICAL TRIAL
Clinical trial information
- Promoter: SPANISH GROUP OF NEUROENDOCRINE TUMORS (GETNE)
- Phase: II
- Execution start: 13/03/2015
- End of execution: 30/10/2017
- IP: ENCARNA GONZALEZ FLORES